IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. : 8160

Appln. No. : 10/597,938

Applicant: Dimitrios Pantelidis et al.

Filed : 08-11-2006

TC/A.U. : 1618

Examiner

Docket No. : **19**53233-00021

Customer No. : 48423

Title: Drug delivery systems using mesoporous oxide films

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-198, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further requests that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

37 CFR §1.97(b). This Information Disclosure Statement should be considered by the Office because:

Applicant: Pantelidis et al. Serial No.: 10/597,938 Group Art Unit: 1618

PATENT 1953233-00021



PATENT 1953233-00021

Applicant: Pantelidis et al. Serial No.: 10/597,938 Group Art Unit: 1618

	37 CFR §1.97(e). A certification signed by an Attorney of Record is provided herewith as required under 37 CFR §§1.97(b) and (c).	
\boxtimes	37 CF	R §1.98(a)(2). The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form PTO/SB/08A are enclosed herewith. OR -
		Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08A are NOT enclosed. AND/OR -
		Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Forms PTO/SB/08A-B are enclosed in accordance with 37 CFR §1.98(a)(2). AND/OR -
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).
	37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or references.	
		Pursuant to 37 CFR §198(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith. AND/OR -
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation of the non-English language reference(s) is provided herewith. AND/OR -
		A copy of the European Search Report indicating the relevance of the non- English language reference(s) is provided herewith
	Attached are copies of search report(s) from corresponding patent application(s), submitted in accordance with MPEP 609 D in support of the attached certification under 37 CFR §1.97(e)(1).	
\boxtimes	No Fees Due. Applicants believe no fee is due with this filing, however, if it is deemed that a fee is due, the Director is hereby authorized to charge any fees or credit any overpayments to Deposit Account No. 50-3207.	

Applicant: Pantelidis et al. PATENT Serial No.: 10/597,938 1953233-00021

Group Art Unit: 1618

 \boxtimes Fee Authorization. The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-3207.

Respectfully submitted,

/Michelle S. Glasky/ Dated: <u>7 July 2009</u> By: Michelle S. Glasky, Ph.D. / Reg. 54124

K&L GATES

1900 Main Street, Suite 600 Irvine, California 92614-7319

Tel: (949) 253-0900

Email: ocipgroup@klgates.com

Customer No. 48423